Aurion Biotech releases positive 12-month results from phase 1/2 CLARA trial | Optometry Times - Clinical News

Published on October 21, 2025
The trial evaluated the safety, efficacy, and tolerability of AURN001 in patients with corneal edema secondary to corneal endothelial dysfunction.